Shilpa Medicare Limited has received approval from CDSCO, New Delhi for the manufacturing and sale of first time in the World Pemetrexed Ready to Use injections 10 ml, 50 ml, 85 ml, and 100 ml in India. Shilpa will commercialize the product under the brand name VRTU. VRTU 10 ml, 50 ml, 85 ml, and 100 ml will be launched immediately.

Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India, for the treatment of metastatic Non‐Squamous Non‐Small Cell Lung Cancer and Mesothelioma in conjunction with cisplatin. A substantial advancement in cancer therapy has been made with this crucial milestone, giving patients and medical professionals fresh hope.

With the commitment towards Thoughtful Innovation for Powerful Outcomes, Shilpa's First‐in‐the‐World - Vrtu 100mg/10ml, Vrtu 500mg/50ml, Vrtu 850mg/85ml, Vrtu 1000mg/100ml Ready to Use formulation will allow physicians and patients to administer directly without any reconstitution and avoid dilution errors and reduce man hours. VRTU is backed by required scientific proof and comparative Bioequivalence & Toxicology studies.

The first‐time launch of Vrtu, Ready to Use is a new formulation drug in India. The composition of VRTU is protected by a granted patent in India until November 2033. It will offer great benefits in terms of flexibility of dosage and patient convenience in specific cancer indications, and advantageous in reducing disposables usage and delivering the appropriate dosing to the patient without any dosing errors over currently available conventional Pemetrexed.

"Pemetrexed Injection is a folate analog metabolic inhibitor indicated: In combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non‐squamous NSCLC, with no EGFR or ALK genomic tumor aberrations. In combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non‐squamous, non‐small cell lung cancer (NSCLC)."

Shilpa Medicare Limited is a research‐driven, global, integrated pharmaceutical company, headquartered in Raichur, Karnataka, India, and is engaged in research and development, manufacturing and sale of oncology drugs and formulations.